
EVAX Stock Forecast & Price Target
EVAX Analyst Ratings
Bulls say
Evaxion AS has demonstrated a significant improvement in the prediction accuracy of its PIONEER AI model, with 81% of predicted neoantigens showing immunogenicity, an increase from the previous year's metrics. Additionally, the clinical data indicates a promising overall response rate (ORR) of 75% for EVX-01 in combination with pembrolizumab, surpassing earlier results and establishing a favorable safety profile compared to competitors in the field. The continuous success of these findings positions Evaxion to potentially attract strategic partnerships for late-stage development and commercialization, enhancing the outlook for the company's stock.
Bears say
Evaxion AS's stock experienced a negative reaction, despite a strong data update regarding its EVX-01 candidate, as investor expectations for a definitive assessment of EVX-01’s contribution to overall performance were not met. This suggests a disconnect between audience anticipation and the company’s ability to provide tangible results, potentially undermining investor confidence. Furthermore, the recommendation to accumulate EVAX on weakness indicates that market sentiment is currently cautious and uncertain about the company's immediate prospects.
This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.
EVAX Analyst Forecast & Price Prediction
Start investing in EVAX
Order type
Buy in
Order amount
Est. shares
0 shares